11月25日,CDE官网显示,和誉医药其自主研发的高选择性小分子FGFR4抑制剂依帕戈替尼 (Irpagratinib/ABSK011) 临床申请获CDE受理,注册分类为1。依帕戈替尼(ABSK-011)是一种高选择性小分子FGFR4抑制剂,被开发用于治疗FGF19过表达的晚期肝细胞癌(aHCC)。此前2025年5月,依帕戈替尼获CDE批准治疗肝细胞癌(HCC)的突破性疗法认定,是首个采用靶向...
Source Link11月25日,CDE官网显示,和誉医药其自主研发的高选择性小分子FGFR4抑制剂依帕戈替尼 (Irpagratinib/ABSK011) 临床申请获CDE受理,注册分类为1。依帕戈替尼(ABSK-011)是一种高选择性小分子FGFR4抑制剂,被开发用于治疗FGF19过表达的晚期肝细胞癌(aHCC)。此前2025年5月,依帕戈替尼获CDE批准治疗肝细胞癌(HCC)的突破性疗法认定,是首个采用靶向...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.